Stockscreener 앱 받기
1.75
1.74%
0.03
시간 외 거래:
1.74
-0.01
-0.57%
전일 마감가:
$1.72
열려 있는:
$1.75
하루 거래량:
592.53K
Relative Volume:
1.60
시가총액:
$48.97M
수익:
-
순이익/손실:
$-64.47M
주가수익비율:
-0.2829
EPS:
-6.1852
순현금흐름:
$-52.33M
1주 성능:
-4.37%
1개월 성능:
-26.16%
6개월 성능:
-63.31%
1년 성능:
-92.30%
1일 변동 폭
$1.71
$1.80
1주일 범위
$1.68
$1.97
52주 변동 폭
$1.56
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
1.75 | 48.13M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Bragar Eagel & Squire is Investigating Certain Officers and - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages - Defense World
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Yahoo Finance
Jasper Therapeutics to Present at Upcoming Investor Conferences - Sahm
Jasper Therapeutics, Inc. (NASDAQ: JSPR) Investor Alert: Deadline in Lawsuit on November 18, 2025 - openPR.com
DEADLINE ALERT for NX, JSPR, and KBR: The Law Offices of - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Markets Financial Content
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit - Business Wire
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors - GlobeNewswire
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Jasper Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, - GlobeNewswire
Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
JSPR DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Jasper Therapeutics, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages - GlobeNewswire
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
Bank of Montreal Can Has $878,000 Stock Position in Jasper Therapeutics, Inc. $JSPR - Defense World
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
William Blair Has Negative Outlook of JSPR FY2025 Earnings - Defense World
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Th - GuruFocus
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
JSPR Shareholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
International Business Times - Markets Financial Content
JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025JSPR - MarketScreener
Jasper Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsJSPR - Stock Titan
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - MarketScreener
JSPR DEADLINE ALERT: ROSEN, TOP RANKED INVESTOR RIGHTS - GlobeNewswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RBC Capital Maintains Jasper Therapeutics (JSPR) Sector Perform Recommendation - Nasdaq
Jasper Therapeutics stock price target lowered to $4 at RBC on BEACON concerns - Investing.com Canada
A look into Jasper Therapeutics Inc (JSPR)’s deeper side - Setenews
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Get in on Rani Therapeutics Holdings Inc’s (RANI) buy-in window today! - setenews.com
RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk - MarketScreener
Jasper Therapeutics Reports Q3 2025 Financial Results - TipRanks
JSPR DEADLINE ALERT: ROSEN, A TOP-RANKED LAW FIRM, - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit, and Molina to Contact the Firm About their Rights - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) - GlobeNewswire
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29) - TipRanks
Jasper Therapeutics, Inc. SEC 10-Q Report - TradingView
[10-Q] Jasper Therapeutics, Inc. Quarterly Earnings Report | JSPR SEC FilingForm 10-Q - Stock Titan
Jasper Therapeutics Q3 loss smaller than estimates - MarketScreener
[8-K] Jasper Therapeutics, Inc. Reports Material Event | JSPR SEC FilingForm 8-K - Stock Titan
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.88%
자본화:
|
볼륨(24시간):